全球朊病毒疾病治疗市场规模、份额、趋势和成长分析报告（2026-2034年）

预计朊病毒疾病治疗市场将从 2025 年的 49 亿美元成长到 2034 年的 78.2 亿美元，2026 年至 2034 年的复合年增长率为 5.33%。

全球朊病毒病治疗市场规模相对小规模，但由于朊病毒相关神经系统疾病的致命性和进行性，这个市场至关重要。例如，库贾氏病等疾病儘管根治性治疗方法有限，但仍需要专业的医疗管理。神经科对朊病毒病的认识不断提高，以及诊断影像和脑脊髓液检测技术的进步，正推动着早期检出率的提升。此外，罕见疾病和孤儿疾病研究经费的增加也促进了市场的发展。目前，支持性治疗和实验性治疗方法在朊病毒病治疗领域占据主导地位。

研究机构和生技公司正积极探索针对异常朊病毒蛋白累积的疾病修正治疗。分子生物学和神经退化性疾病研究的进展正在开闢新的研究途径。已开发国家政府为孤儿药提供优先待遇，以促进罕见疾病治疗领域的创新。改进的监测系统正在加强病例识别和流行病学追踪。合作研究倡议进一步推动了该领域的科学进步。

未来市场成长将主要取决于标靶治疗和早期诊断工具的突破性进展。对精准医疗和生物标记开发的日益重视有望加速治疗创新。扩大临床试验和国际研究合作可望增进我们对朊病毒疾病发病机制的理解。儘管患者数量仍然较少，但巨大的未满足需求将继续推动投资。随着科学进步不断改善治疗方案，市场预计将稳定成长。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章：全球朊病毒疾病治疗市场：依类型划分

• 市场分析、洞察与预测
• 库贾氏病（CJD）
• 变异型库贾氏病(vCJD)
• 变异型蛋白酶敏感朊病毒病
• 格斯特曼-施特劳斯勒-沙因克病
• 其他的

第五章：全球朊病毒疾病治疗市场：依药物划分

• 市场分析、洞察与预测
• 抗忧郁症
• 抗精神病药物
• 其他的

第六章：全球朊病毒疾病治疗市场：依给药途径划分

• 市场分析、洞察与预测
• 口服
• 注射

第七章 全球朊病毒疾病治疗市场：依最终使用者划分

• 市场分析、洞察与预测
• 医院
• 居家照护
• 专科诊所
• 其他的

第八章 全球朊病毒疾病治疗市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第九章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第十章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Thermo Fisher Scientific Inc
  • Illumina Inc
  • Bio-Rad Laboratories Inc
  • F. Hoffmann-La Roche Ltd
  • Oncocyte Corporation
  • Johnson & Johnson Services Inc
  • PathAI Inc
  • Guardant Health
  • Labcorp
  • Sysmex Inostics Inc
  • Sangamo Therapeutics Inc
  • Voyager Therapeutics Inc
  • Merck & Co. Inc
  • Genentech Inc

The Prion Disease Treatment Market size is expected to reach USD 7.82 Billion in 2034 from USD 4.90 Billion (2025) growing at a CAGR of 5.33% during 2026-2034.

The Global Prion Disease Treatment Market is relatively niche but critically important due to the fatal and progressive nature of prion-related neurological disorders. Conditions such as Creutzfeldt-Jakob disease require specialized medical management, even though effective curative therapies remain limited. Growing awareness among neurologists and advancements in diagnostic imaging and cerebrospinal fluid testing are improving early detection rates. Increased research funding for rare and orphan diseases is also contributing to market development. Supportive care and experimental therapeutic approaches currently dominate the treatment landscape.

Research institutions and biotechnology companies are actively exploring disease-modifying therapies targeting abnormal prion protein accumulation. Advances in molecular biology and neurodegenerative disease research are opening new investigative pathways. Governments in developed countries are offering orphan drug incentives, encouraging innovation in rare disease therapeutics. Improved surveillance systems are strengthening case identification and epidemiological tracking. Collaborative research initiatives are further supporting scientific progress in this field.

Looking ahead, the market's future growth depends largely on breakthroughs in targeted therapies and early diagnostic tools. Increasing focus on precision medicine and biomarker development may accelerate treatment innovation. Expanded clinical trials and global research partnerships are expected to enhance understanding of prion pathogenesis. Although patient numbers remain small, high unmet medical need will continue to drive investment. The market is projected to grow steadily as scientific advancements improve therapeutic possibilities.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Types

• Creutzfeldt-Jakob Disease (CJD)
• Variant Creutzfeldt-Jakob Disease (CJD)
• Variably Protease-Sensitive Prionopathy
• Gerstmann-Straussler-Scheinker Disease
• Others

By Drug

• Antidepressant
• Antipsychotic Agents
• Others

By Route of Administration

• Oral
• Injectable

By End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

COMPANIES PROFILED

• Thermo Fisher Scientific Inc, Illumina Inc, BioRad Laboratories Inc, F HoffmannLa Roche Ltd, Oncocyte Corporation, Johnson Johnson Services Inc, PathAI Inc, Guardant Health, Labcorp, Sysmex Inostics Inc, Sangamo Therapeutics Inc, Voyager Therapeutics Inc, Merck Co Inc, Genentech Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL PRION DISEASE TREATMENT MARKET: BY TYPES 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Types
• 4.2. Creutzfeldt-Jakob Disease (CJD) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Variant Creutzfeldt-Jakob Disease (CJD) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Variably Protease-Sensitive Prionopathy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Gerstmann-Straussler-Scheinker Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PRION DISEASE TREATMENT MARKET: BY DRUG 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Drug
• 5.2. Antidepressant Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Antipsychotic Agents Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PRION DISEASE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Route Of Administration
• 6.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL PRION DISEASE TREATMENT MARKET: BY END USER 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast End User
• 7.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Homecare Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Specialty Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL PRION DISEASE TREATMENT MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Types
  • 8.2.2 By Drug
  • 8.2.3 By Route Of Administration
  • 8.2.4 By End User
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Types
  • 8.3.2 By Drug
  • 8.3.3 By Route Of Administration
  • 8.3.4 By End User
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Types
  • 8.4.2 By Drug
  • 8.4.3 By Route Of Administration
  • 8.4.4 By End User
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Types
  • 8.5.2 By Drug
  • 8.5.3 By Route Of Administration
  • 8.5.4 By End User
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Types
  • 8.6.2 By Drug
  • 8.6.3 By Route Of Administration
  • 8.6.4 By End User
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL PRION DISEASE TREATMENT INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Thermo Fisher Scientific Inc
  • 10.2.2 Illumina Inc
  • 10.2.3 Bio-Rad Laboratories Inc
  • 10.2.4 F. Hoffmann-La Roche Ltd
  • 10.2.5 Oncocyte Corporation
  • 10.2.6 Johnson & Johnson Services Inc
  • 10.2.7 PathAI Inc
  • 10.2.8 Guardant Health
  • 10.2.9 Labcorp
  • 10.2.10 Sysmex Inostics Inc
  • 10.2.11 Sangamo Therapeutics Inc
  • 10.2.12 Voyager Therapeutics Inc
  • 10.2.13 Merck & Co. Inc
  • 10.2.14 Genentech Inc